临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 442-51-3

Harmine

中文名称:哈尔碱; 哈尔明碱; 肉叶云香碱; 去氢骆驼蓬碱
CAS号:442-51-3
分子式: C13H12N2O 分子量: 212.25
产品形式: free base
研发状态: Recruiting
研发用途: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
研究机构: Insel Gruppe AG University Hospital Bern; Psychiatric University Hospital Zurich
研发日期: January 22 2024
研发阶段: Phase 1
Harmine (Telepathine), a fluorescent harmala alkaloid belonging to the beta-carboline family of compounds, is a highly cell-permeant and competitive inhibitor of ATP binding to the kinase pocket of DYRK1A, with about 60-fold higher IC50 value for DYRK2. Harmine also inhibits monoamine oxidases (MAOs), PPARγ and cdc-like kinases (CLKs). Harmine inhibits 5-HT2A serotonin receptor with Ki of 397 nM.

CAS: 441798-33-0

Macitentan (ACT 064992)

中文名称: 马西替坦
CAS号:441798-33-0
分子式: C19H20Br2N6O4S 分子量: 588.27
产品形式: free base
研发状态: Recruiting
研发用途: Arterial Hypertension Pulmonary
研究机构: Actelion
研发日期: March 14 2024
研发阶段: Phase 1
Macitentan (ACT 064992) is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.

CAS: 434-13-9

Lithocholic acid

中文名称:石胆酸
CAS号:434-13-9
分子式: C24H40O3 分子量: 376.57
产品形式: free base
研发状态: Completed
研发用途: Obesity
研究机构: North Dakota State University
研发日期: Jan-16
研发阶段: --
Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity, its toxic effect can be protected after it activates the vitamin D receptor, PXR and FXR.

CAS: 43229-80-7

Formoterol Hemifumarate

中文名称:富马酸福莫特罗
CAS号:43229-80-7
分子式: C19H24N2O4.1/2C4H4O4 分子量: 402.40
产品形式: Hemifumarate
研发状态: Recruiting
研发用途: Asthma
研究机构: Sanofi
研发日期: October 16 2023
研发阶段: Phase 2
Formoterol Hemifumarate (Eformoterol, CGP 25827A, NSC 299587, YM 08316,Formoterol fumarate) is a potent, selective and long-acting β2-adrenoceptor agonist used in the management of asthma and chronic obstructive pulmonary disease(COPD).

CAS: 43218-56-0

Midodrine hydrochloride

中文名称:盐酸米多君
CAS号:43218-56-0
分子式: C12H19ClN2O4 分子量: 290.74
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Heart Failure With Reduced Ejection Fraction; Hypotension; LV Dysfunction
研究机构: Ottawa Heart Institute Research Corporation
研发日期: August 1 2024
研发阶段: Phase 2 : Phase 3
Midodrine hydrochloride is the hydrochloride salt form of midodrine, an adrenergic alpha-1 agonist used as a vasopressor.

CAS: 4291-63-8

Cladribine (RWJ 26251)

中文名称:克拉利宾
CAS号:4291-63-8
分子式: C10H12ClN5O3 分子量: 285.69
产品形式: free base
研发状态: Recruiting
研发用途: Multiple Sclerosis
研究机构: Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
研发日期: August 3 2023
研发阶段: --
Cladribine (RWJ 26251, Leustatin, 2-CdA, 2-chlorodeoxyadenosine, 2-Chloro-2′-deoxyadenosine, CldAdo, Jk 6251, NSC 105014) is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50 of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively.